ICER Atopic Dermatitis Review Prompted By First Biologic

The Institute for Clinical and Economic Review’s assessment of emerging therapies for atopic dermatitis was driven by both excitement and concern from physicians and payers over the anticipated launch of Regeneron/Sanofi’s dupilumab.

The Institute for Clinical and Economic Review (ICER) decision to develop an assessment report on the effectiveness and value of emerging therapies for the treatment of atopic dermatitis was prompted mainly by the anticipated launch of Regeneron Pharmaceuticals Inc./Sanofi’s Dupixent (dupilumab), the first biologic to treat the condition, Chief Scientific Officer Daniel Ollendorf said in an interview.

The non-profit research institute announced plans to assess the atopic dermatitis drug space Oct. 19. Dupixent is pending at FDA...